Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BGMA/BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Better access. Better health.
The British Generic Manufacturers Association (BGMA) represents the interests of UK-based manufacturers and suppliers of generic and biosimilar medicines and promotes the development and understanding of the generic and biosimilars medicines industry in the United Kingdom.
We have a strong focus on quality
The British Generic Manufacturers Association (BGMA) has launched a forum in conjunction with the MHRA to focus on ensuring the manufacturing quality of generic medicines in the UK.
We reflect our members’ views at UK and European levels
We represent the views and interests of our members and industry generally to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union and the media. Find out more about joining us.

Twitter

21.05.2018
RT @pharmaintegrate: #Brexit Remains a Significant Risk to the Continuous and Undisrupted Supply of #Medicines Says #BGMA https://t.co/986vr9YYLq @Britishgenerics
17.05.2018
RT @CommonsBEIS: Chair @RachelReevesMP on this morning's report on Brexit and pharmaceuticals. Watch her @HouseofCommons statement, due after 11am today. https://t.co/inD7CrMcrX
17.05.2018
RT @CommonsBEIS: Chair @RachelReevesMP is speaking in @HouseofCommons on our report on the impact of Brexit on pharmaceuticals. https://t.co/SGE5akbvB5. The report is the last in a series of studies on the impact of Brexit on different sectors of the economy. Watch here: https://t.co/inD7CrMcrX
17.05.2018
Read our reaction to the @beisgovuk report on the impact of Brexit on the pharmaceutical sector - we agree patien… https://t.co/nTldSkpu
17.05.2018
RT @medicinesforEU: Do you want to know more about the sustainability of the off-patent #pharmaceutical markets? Join us at the #IGBAmedicinesforEU conference in Budapest on 13-15 June and discuss with the panel of experts! https://t.co/o4yLmq5RXn

10 things you need to know

1
Generic medicines meet the same standards of quality, safety and efficacy as originator brands.
2
Generics have to demonstrate that they are bioequivalent to the original product - i.e., they deliver equal medical benefits to the patient.
3
Generic competition saves the NHS more than £13.5bn per annum.
4
The average cost to the NHS of a generic medicine is £3.80, whilst the average cost of a branded medicine is £20.95.
5
On one product alone, based on current usage, the generics industry has saved the taxpayer £1.1bn.
6
In the UK, a free market approach with competition between manufacturers and incentives for GPs to prescribe and pharmacists to dispense generics has led to a high market share (76%) for generic products.
7
Generic prices in the UK are the lowest in the developed world and are constrained by free market competition.
8
The market share that generics reach and the savings they generate are dependent upon national legislation and regulation.
9
Further growth and NHS savings are constrained by regulatory delays and costs, and the actions of some originator companies in trying to avoid or delay generic competition.
10
Competition from generics also stimulates the research based pharmaceutical industry to develop new medicines.